在全球肥胖症发病率持续攀升的背景下,有效且便捷的体重管理方案成为医学界与公众关注的焦点。近日,《新英格兰医学杂志》(The New England Journal of Medicine)发表了来自3期试验OASIS 4的结果:每日一次口服司美格鲁肽片25 mg(Wegovy®片剂)在肥胖或超重成人中实现了16.6%的平均体重减轻,且每3名受试者中就有1人减重超过20%。这一成果不仅标志着口服...
Source Link在全球肥胖症发病率持续攀升的背景下,有效且便捷的体重管理方案成为医学界与公众关注的焦点。近日,《新英格兰医学杂志》(The New England Journal of Medicine)发表了来自3期试验OASIS 4的结果:每日一次口服司美格鲁肽片25 mg(Wegovy®片剂)在肥胖或超重成人中实现了16.6%的平均体重减轻,且每3名受试者中就有1人减重超过20%。这一成果不仅标志着口服...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.